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Hybrid QM/MM calculations on adducts of five platinum-based anti-cancer drugs, namely cisplatin,
oxaliplatin, lobaplatin, and heptaplatin are reported. Starting from the NMR structure of a cisplatin–DNA
octamer complex (PDB entry 1AU5), we compare DNA binding of drugs that differ in their carrier ligands,
and hence in their potential interactions with DNA. It is shown that all drugs induce broadly similar
changes to the regular helical structure of DNA, but that variations in ligand lead to subtle differences in
complex geometry, with cisplatin exhibiting notably different properties to other drugs. Cisplatin is also
the most weakly bound of drugs considered here, and heptaplatin the most strongly bound. Differences in
binding appear to be due to changes in the pattern of non-covalent interactions between drug and DNA,
especially hydrogen bonding to oxygen in guanine and phosphate groups. Despite adopting very similar
geometries, two isomers of lobaplatin (RRS and SSS) are found to have quite different binding energies,
the latter being bound by up to 30 kcal mol21 more than the former.
Introduction
Cisplatin (1, cis-[PtCl2(NH3)2]) is one of the best-selling anti-
cancer drugs of recent times.1,2 Despite its success, serious
drawbacks related to toxicity and resistance3 mean that the
search for deeper understanding of its mode of action, and for
therapeutic alternatives, continues to be intense.4 To date, the
only other drugs with global approval are carboplatin and
oxaliplatin (2) (see Fig. 1) while others such as nedaplatin,
heptaplatin (3) and lobaplatin (4) have found approval locally.5
All such complexes enter cells intact, and are then hydrolyzed
to yield active aqua/hydroxo species via loss of anionic
ligand(s). These active species then form adducts with
nucleophilic sites in DNA within the cell nucleus, particularly
the N7 position of guanine. Mono- adducts as well as inter-
and intra-strand cross-links are possible, with the latter
dominating, and the resulting distortion of the DNA helix
give rise to recognition by repair proteins and ultimately cell
apoptosis.3,5
Carboplatin and nedaplatin yield the same active species as
cisplatin on loss of anionic ligand, and hence are likely to
share in fundamental mechanism of action, but have
improved pharmacokinetics and reduce toxicity due to a
chelate effect. Oxaliplatin is a third generation platinum
anticancer drug with a 1,2-diaminocyclohexane (DACH) entity,
predominantly used in the treatment of colorectal cancer.6 In
this and related drugs like heptaplatin and lobaplatin,
ammine carrier ligands are replaced by larger chelating
amines that improve cell uptake by their greater hydrophobi-
city, as well as forming different interactions with DNA.
Oxaliplatin forms fewer crosslinks than cisplatin at equimolar
concentrations, as its adducts are bulkier and more hydro-
phobic than those formed from cisplatin or carboplatin,
leading to different effects in the cell.7 Lobaplatin and
heptaplatin similarly employ large, chelating amines.
Oxaliplatin and heptaplatin are administered as single
enantiomers, but lobaplatin is a nearly 50/50 mixture of two
diastereoisomers (SSS and RRS configurations).
A recent NMR study of adducts of cisplatin and oxaliplatin
with a DNA dodecamer showed subtle differences in the
orientation of platinated bases that ultimately give rise to the
different spectrum of activity of the drugs.8 Such experiments
give detailed insight into the drug–DNA interaction, but can be
expensive and time-consuming, and cannot be used for virtual
screening of as-yet unsynthesized drugs. A reliable and general
method to predict how a particular platinum complex may
interact with DNA could be a valuable complement to the tools
available in designing new and improved platinum-based anti-
cancer drugs. A great many theoretical studies have addressed
the structure and properties of platinum drugs,9 their mode(s)
of activation and deactivation,10 and interaction with DNA.11
Density functional theory (DFT) is a very popular way to
include electron correlation effects, and thus obtain accurate
description of drugs, for relatively little computational
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expense. However, even with modern computing resources
such studies are limited to perhaps a few hundred atoms,
corresponding to small portions of DNA. Molecular mechanics
(MM) methods allow study of much larger systems such as
DNA oligomers, but require specific parameters for all atoms
and bonds present. Such parameters have been reported and
applied for cisplatin and oxaliplatin,12 but this approach is not
generally applicable to all the drugs under study here.
Hybrid QM/MM approaches offer a middle way that
preserves the accuracy of DFT in describing transition metals
with the applicability to large systems of MM. QM/MM studies
of nucleic acids are relatively rare, at least when compared to
analogous studies of enzymes, and such studies of metal–DNA
interactions are still rarer. Several pioneering studies
employed Car–Parrinello molecular dynamics to probe bind-
ing of cisplatin and other Pt complexes to DNA,13 while others
have recently addressed aspects of several transition metal
drugs.14 In a recent study,15 we set out an efficient QM/MM
scheme for simulation of platinum-DNA adducts, testing
against crystal and NMR data for cisplatin complexed with a
DNA dimer and octamer, respectively. This showed that DFT/
MM gas-phase optimisation accurately reproduces dimer
structures, but that explicit solvation is required to properly
describe larger DNA segments. In this work, we apply the same
methods to compare binding of drugs with varying carrier
ligand.
Computational methods
Following our previous studies of cisplatin, QM/MM calcula-
tions were performed with the two-level ONIOM method16
within the Gaussian 09 suite of programs.17 Specifically,
BHandH DFT method along with a 6-31+G(d,p) basis set on
light atoms and SDD basis set and effective core potential on
Pt 18,19 was used for the high layer, and AMBER (parm96) for
the low layer.20 This approach has been shown to reproduce
p-stacking potential energy curves and structures of DNA
fragments and their metal complexes.15 Hydrogen link atoms
replaced carbon at the base–sugar bond, such that bases
directly attached to platinum are treated with DFT and all
remaining atoms with AMBER. In ref. 15, we showed that
generic parameters for metal–ligand bond lengths and angles
satisfactorily describe atoms in the high layer: the same
approach is used throughout this work. Replacement of the C–
N bond in the full system with a C–H bond in the high layer of
an ONIOM calculation is not expected to drastically alter the
electronics of the system. An example of this partitioning
scheme is shown in Fig. 2. Atomic charges were assigned
manually to each atom in the low layer, and high layer charges
determined by a restrained fit to the electrostatic potential
(RESP) via the Merz–Kollman procedure.21 Electrostatic
embedding, in which the QM region is polarised by the
charges in the MM region was employed, following our
findings in ref. 15 that lack of such embedding leads to poor
reproduction of experimental data.
Fig. 1 Molecular structures of current platinum based drugs, with chiral centres indicated by an asterisk.
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Geometry optimisation was performed using the GDIIS (for
smaller systems) and GEDIIS (for octamers) methods.22 Dimer
and octamer structures were generated from the NMR
structure of cisplatin with ds- CCTG*G*TCC (* indicating sites
of platination: PDB entry 1AU5).23 Sodium ions were added ca.
2 Å from each phosphate, resulting in an overall complex
charge of +2. Dimers were optimised in gas-phase, while
octamer complexes were solvated by a large cubic box of water
in Molecular Operating Environment (MOE) software,24 which
was then truncated by use of a cut off of solute–solvent
distance, above which solvent molecules are ignored, to retain
approximately 100 solvent molecules, resulting in a total of
approximately 800 atoms. Geometries were fully optimised in
all cases, but vibrational frequency analysis is beyond our
capability at present. Aqueous-phase binding energy calcula-
tions employed the polarizable continuum model (PCM)
approach, and in particular the ONIOM-PCM method in
which reaction field is computed only for the real-system at
the low-level while the sub-calculations on the model-systems
are performed assuming zero reaction field.25 Analysis of the
resulting DNA structures was performed using the X3DNA
software.26
Results and discussion
In order to have confidence in the ability of our QM/MM
model to accurately describe drug–DNA interactions, we first
summarize its ability to reproduce the experimental geometry
of cisplatin–DNA dimer and octamers.15 A crystal structure of
cisplatin bound to single stranded guanine-deoxyribose
phosphate-guanine, d(GpG), that contains four independent
molecules in the unit cell was used as the first test. QM/MM
optimized geometry reproduces almost all experimental bond
lengths and angles to within one standard deviation (sd) of
experimental data (see ESI3). A key parameter for the
disruption of native DNA structure by platination is the angle
between mean planes of guanines: the experimental value for
this is 81.2 ¡ 4.3u, while our predicted value is 86.5u.
A more stringent test of our approach lies in its ability to
reproduce the geometry of cisplatin bound to longer sections
of double-stranded DNA. Table 1 reports such a comparison,
concentrating on the base-pair step parameters obtained from
X3DNA analysis. Agreement with NMR data is generally
reasonable, especially when comparing average values across
the entire sequence. Deviations from experiment are some-
what larger for the platinated GG/CC base pair step, but key
aspects of platinated DNA and its deviation from the ideal
B-form of DNA are reproduced. It is important to note that
NMR experiments result in a family of structures that satisfy
observed coupling and NOE data. For instance, ref. 23 reports
the distance between H8 protons on G4 and G5 to lie between
2.52 and 3.92 Å, with an average value quoted in the PDB entry
of 2.907 Å: our QM/MM optimized value of 3.757 Å is therefore
significantly different from the reported value but actually lies
comfortably within the range of acceptable distances. While
the PDB entry used for the octamer complex (1AU5) reports
just one structure, entry 2NQ0 (cisplatin–DNA dodecamer)
reports 15 structures that satisfy NMR observations. Analysis
of all 15 structures indicates that significant variation of base-
pair step parameters exists within the family: shift exhibits
variation of 0.45 Å, slide 1.12 Å, raise 0.71 Å, tilt 1.7u, roll 10.0u
and twist 8.5u. In this context, the level of agreement between
experimental and theoretical data in Table 1 is satisfactory.
Fig. 2 QM/MM optimized geometry of SSS 4 complexed to (a) GG/CC base-pair
step, and (b) d(CCTGGTCC).
Table 1 Comparison of QM/MM and NMR geometry of cisplatin–octamer
complex (Å and u)
Shift Slide Rise Tilt Roll Twist
G4-G5
Experiment 1.20 21.55 +5.50 213.18 +58.72 +23.24
QM/MM 0.92 21.94 +4.97 25.64 +48.00 +35.17
Average
Experiment 20.14 20.02 +3.63 20.46 +4.13 +33.24
QM/MM 20.12 20.20 +3.55 23.16 +5.56 +35.04
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Following these tests on cisplatin, similar methods were
used to compare the DNA adducts of 1, 2, 3, and both isomers
of 4. Initially, each drug was manually complexed with a GG/
CC base pair step taken from PDB entry 1AU5, then QM/MM
optimized. Representative examples of optimized structures
are shown in Fig. 2, which also serves to illustrate the partition
between QM and MMM layers employed. Coordination
geometry varies little between drugs (see ESI3), with the
exception of the N1–Pt–N2 angle for 2, which is around 10u
less than in other complexes. The distortion of the helical DNA
structure in these complexes, as determined by the angle
between guanine planes, is much less in these double-
stranded complexes than in the single-stranded example
discussed above, with values between 25 and 28u. Analogous
data for QM/MM optimised complexes with octameric DNA are
also reported: Pt–N7 bond length to the 39 guanine is slightly
shorter (0.02–0.03 Å) in the octamer than the dimer, while in
several cases the angle formed by the carrier ligand amines’
coordination to Pt varies by as much as 7u. However, in
general, the square-planar coordination geometry does not
vary greatly between the two forms of DNA.
More detailed information on the DNA conformation is
reported in Table 2. These data highlight the consistent
deviations from the unbound DNA structure, optimised at the
same level. In the dimers, platination gives rise to larger shift
and smaller rise values than in free DNA, whereas slide values
are barely affected. Similarly, roll values are significantly larger
(more positive) and twist is slightly smaller in platinated
complexes than in free DNA, but tilt values are close to their
undistorted values. Within these overall trends, some changes
due to the nature of the carrier ligand are evident: for instance,
heptaplatin induces a noticeably smaller roll value than all
other complexes considered here. Also, differences between
RRS and SSS lobaplatin are rather large in some cases,
especially shift and slide. However, on the whole Table 2
indicates that platination induces similar changes to DNA no
matter what ligand is present. Base pair data (ESI3) show that
shear values are uniformly more negative in the complexes
than in free DNA, but stagger and especially stretch are close to
the uncomplexed values. Similarly, propeller values differ from
free DNA, but buckle and opening values are similar to free
values. However, heptaplatin makes an exception from this
overall trend, displaying markedly different stagger and
propeller values in its 39G–59C base pair than other complexes
or free DNA, indicating significant out-of-plane distortion of
this base pair that is not present in others. Unlike in the base
pair step data, differences in base pair parameters between
chiral forms of lobaplatin are small.
Analogous data for octameric complexes with drugs 1 to 4
are also reported in Table 2, and illustrated in Fig. 3,
concentrating on the central GG/CC base pair. In all
complexes, platination induces a bending of the helix towards
the major groove, with a tendency to enclose the drug. This
bending of the helix brings bulky Pt ligands spatially close to
nucleobases other than those of the site of platination (G4,
G5), therefore possibly giving rise to additional non-bonded
interactions between atoms of the QM and MM regions. All
complexes show large positive shift values, in contrast to the
small negative value in free DNA, and slightly more negative
slide values than free DNA. Twist parameters exhibit uniform
displacement from the values in free DNA, and are slightly less
positive than in free DNA. Tilt values change by only very small
amounts across the series, and no clear trend is apparent. The
clearest differences between drugs are found in the separation
between base pairs: the cisplatin complex exhibits a smaller
rise value than other drugs, similar to that in free DNA,
whereas all other drugs give larger rise values. A similar trend
Table 2 Base-pair step geometries for platinated GC pairs (Å and u). First line
reports values for dimer, second line octamer.
Shift Slide Rise Tilt Roll Twist
1 1.43 21.75 3.36 20.4 13.6 31.3
1.14 21.11 3.18 28.0 28.5 22.9
2 1.42 21.85 3.42 20.7 14.0 31.6
1.33 21.61 3.64 +1.9 46.2 28.7
3 1.47 21.71 3.39 21.8 6.9 28.8
0.99 21.35 3.51 23.1 42.6 22.1
4 RRS 1.39 21.77 3.32 21.8 12.7 28.2
1.12 21.13 3.71 20.8 43.6 24.8
4 SSS 1.54 21.94 3.40 21.7 11.2 30.8
1.00 21.13 3.61 24.7 45.0 20.3
DNAa 0.87 21.73 3.83 +2.3 21.0 36.2
20.40 20.57 3.09 28.3 7.9 34.3
a Obtained from optimization of DNA using the same methods.
Fig. 3 Central GG/CC base-pair step geometry of drug–octamer complexes (Å
and u).
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is evident in the roll parameter: cisplatin has notably smaller
roll values than the remaining complexes, although this is still
much greater than in free DNA. Differences between the
isomeric forms of 4 are generally very small in this data, and
both exhibit broadly similar geometry to 3.
The binding energy of each drug to its target is a key factor
in the mode of action. Table 3 reports binding energies of each
drug to DNA dimer and octamer, evaluated in gas- and
simulated aqueous-phase. Binding to octamer is much more
energetically favourable than to the dimer, perhaps due to
additional interactions of ligand with flanking bases or to the
greater number of anionic/cationic charge centres in the larger
strand. Three of the four methods of estimating binding
energy give the same trend, namely 1 , 2 $ 4 RRS , 3 $ 4
SSS. Only the gas-phase dimer values are out of step with the
others; given the likely importance of solvation in binding of a
cationic platinum complex to highly polar DNA as well as the
larger-scale DNA structure, it seems likely that gas-phase
dimer values do not capture some essential feature of binding.
Differences between drugs are larger in gas-phase data than in
simulated solvent, but the remaining three approaches yield
the same trend of binding energy between drugs, with
heptaplatin the most strongly bound and lobaplatin in its
SSS configuration closely behind. 1 is the least strongly bound,
while 2 and RRS 4 have binding energies intermediate between
these extremes. This is illustrated for octamer data in Fig. 4.
The weak binding of 1, and the significant difference between
configurations of 4 (82 kcal mol21 in gas-phase, 31 kcal mol21
in PCM water), are somewhat surprising, and suggest that the
larger drugs may undergo substantial non-covalent interac-
tions with the receptor that are not present in the complex of 1
and/or not optimal in the RRS 4 complex.
To examine the binding of each drug to DNA in more detail,
we have carried out AIM analysis on model systems in which
the optimized octamer structure was truncated to a single-
stranded TGGT sequence,{ since the full system cannot be
evaluated at DFT level. The electron density for each such
model was then evaluated with a full DFT calculation. Table 4
summarizes the covalent and non-covalent interactions
between drug and DNA found for each complex. As expected,
each complex has two covalent linkages between Pt and N7 of
guanine, that are characterized by relatively large (.0.1 au)
values of the electron density at the corresponding critical
point rc. Variation in rc between drugs in these covalent bonds
is relatively small, with all values lying in the range 0.121 to
0.137 au. However, all complexes except that of cisplatin show
markedly greater rc in the bond to 39 guanine than to 59,
reflecting the shorter distances in the octamer noted above.
Table 3 Binding energies DNA dimer and octamer (kcal mol21)
Dimer Gas Aqueous Octamer Gas Aqueous
1 2327.2 256.1 2468.0 2245.4
2 2302.4 256.0 2545.0 2299.6
3 2315.7 269.1 2638.3 2337.1
4 RRS 2304.2 264.5 2537.7 2296.6
4 SSS 2306.5 267.1 2620.1 2327.9
Fig. 4 Binding energy of drugs to octameric DNA (kcal mol21).
Table 4 Summary of AIM data
Complex Drug DNA No. rc (au) NCI
a
1 Pt N7 (G) 2 0.128, 0.128 —
Pt O6 (G59) 1 0.018 s
N–H O6 (G39) 1 0.045 ss
N–H O4 (T39) 1 0.020 s
N–H p (T59) 1 0.011 ws
N–H sugar 59 1 0.003 ws
2 Pt N7 (G) 2 0.126, 0.137 —
Pt O6 (G59) 1 0.012 s
N–H O6 (G39) 1 0.026 ss
N–H O4 (T39) 1 0.018 s
N–H p (T59) 1 0.015 s
N–H OLP (59) 1 0.045 ss
C–H sugar 59 4 0.013, 0.006, 0.005, 0.004 ws
C–H O4 (T39) 1 0.006 ws
3 Pt N7 (G) 2 0.123, 0.132 —
Pt O6 (G59) 1 0.013 s
N–H O6 (G39) 1 0.045 ss
N–H O4 (T39) 1 0.018 s
N–H p (T59) 1 0.009 ws
N–H OLP (59) 1 0.042 ss
C–H T59 5 0.009, 0.008, 0.007, 0.006, 0.004 ws
4 RRS Pt N7 (G) 2 0.121, 0.135 —
Pt O6 (G59) 1 0.012 s
N–H O6 (G39) 1 0.047 ss
N–H p (T39) 1 0.006 s
N–H p (T59) 1 0.017 s
N–H sugar 59 1 0.014 ws
C–H OLP 59 1 0.021 s
C–H sugar 59 1 0.008 ws
C–H T 39 2 0.013, 0.03
4 SSS Pt N7 (G) 2 0.123, 0.132 —
Pt O6 (G59) 1 0.012 s
N–H O6 (G39) 1 0.043 ss
N–H O4 (T39) 1 0.016 s
N–H OLP (59) 1 0.036 ss
N–H p (T59) 1 0.012 ws
N–H sugar 59 2 0.010, 0.009 ws
C–H sugar 59 1 0.008 ws
C–H T59 2 0.010. 0.007 ws
C–H O4 (T39) 1 0.009 ws
a ss = strongly stabilizing; s = stabilizing; ws = weakly stabilizing.
{ Tests on larger fragments with cisplatin, such as double-stranded TGGT,
showed no difference in drug-DNA critical points found.
4070 | RSC Adv., 2013, 3, 4066–4073 This journal is  The Royal Society of Chemistry 2013
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Less expected is the presence of an interaction between Pt and
O6 of the 59 guanine, located over the plane defined by Pt–N
bonds. The long-range nature of this contact (Pt…O = 3.01 Å in
cisplatin complex), and the fact that rc is an order of
magnitude lower than in Pt–N bonds, suggest that this is an
outer-shell effect and that the complexes are indeed best
described as 4-coordinate square planar.
All complexes contain a relatively strong hydrogen bond
linking N–H of coordinated am(m)ine ligand and O6 of the 39
guanine. In most complexes this H-bond has consistent rc
values of around 0.045 au, but in the case of 2 the H-bond is
rather weaker, with rc = 0.026 au. This is reflected in H-bond
distance, 1.96 Å in the complex of 2 compared with 1.72 to
1.75 Å in the remaining complexes. Hydrogen bonds from
coordinated am(m)ine ligand to the 39 thymine are also
common, typically to O4 but in one case to the p-system of this
base. An important difference between complexes appears to
lie in the presence of N–H…OLP H-bonds, which are present
and rather strong in 2, 3 and 4 SSS complexes, i.e. the more
strongly bound drugs, but absent in 1 and 4 RRS ones. Several
of the complexes of larger drugs also contain numerous C–
H…X interactions: this is most obvious in 2 and 3 complexes.
In the former, many of these are of C–H…H–C type to the
pentose sugar and thymine on the 59 side of the drug, which
might appear at first sight to be repulsive, steric contacts. In
the latter, some such contacts are of C–H…H–C type, but
others are C–H…p forming contacts to 59 thymine, which seem
likely to contribute to the overall stabilization of this complex.
The (de)stabilizing nature of such contacts is discussed in
more detail below.
Interestingly, there exists an approximate linear correlation
between binding energy and the sum of rc values found
between drug and DNA, whether including the Pt–N and Pt…O
contacts (R2 = 0.88) or excluding those and only using non-
covalent interactions (R2 = 0.92). We have previously used such
an approach to correlate density properties with binding
energies for purely non-covalent interactions.27 The presence
of such correlations in the current data supports the
hypothesis that non-covalent interactions play an important
role in determining the overall binding of a drug to DNA.
However, it is not always clear from such AIM data whether an
individual interaction acts to stabilize or destabilize. Indeed,
there has been substantial discussion in literature over
whether the presence of a bond critical point unambiguously
indicates a stabilizing interaction.28
To complement AIM analysis, we have also employed the
reduced density gradient s(r) and related properties, as defined
by Johnson et al.’s program NCIPLOT.29 It has been shown
that s(r) identifies non-covalent interactions, and that the
sign(s) of the curvature of the density at relevant points can
distinguish strongly stabilizing (e.g. hydrogen bonds), weakly
stabilizing (e.g. van der Waals) or destabilizing (e.g. steric
clash) contacts. This analysis finds non-covalent regions of
reduced density gradient corresponding to all critical points
located in AIM analysis (see Fig. 5 for an example plot of
oxaliplatin), and indicates that N–H…O hydrogen bonds are
strongly stabilizing, as expected. Weaker stabilization is
indicated for C–H…O and N–H…p contacts, while even those
that may seem like steric C–H…H–C clashes between drug and
sugar are reported to be weakly stabilizing (Johnson et al.
report similar results to ours for the methane dimer).30 NCI
analysis also locates a region of s(r) corresponding to the Pt…O
contact observed in AIM analysis, and assigns this as a
stabilizing interaction, albeit not as strongly so as N–H…O
hydrogen bonds. In this approach, we find no evidence of any
destabilizing contacts between drug and DNA; this confirms
the suitability of including all critical points in the correlations
noted above.
As well as distortion of the regular DNA helix, another
geometrical aspect of the drug complexes that may play a role
in activity is the extent to which the carrier ligand is exposed
and hence able to interact with solvent or be recognized by
repair proteins. Table 5 reports the exposed surface area of
each drug fragment when in complex with dimer and octamer
DNA strands. Values are uniformly smaller in the larger
complexes, albeit by significantly different amounts. The
smallest drug, 1, unsurprisingly has the lowest exposed area
in both complexes, but this barely differs between DNA
strands. In contrast, 2 has a high exposed area when bound
to a DNA dimer, but this is much reduced in the octamer
which may suggest a close fit between the ligand and receptor.
4 in its RRS form shows a similar reduction in exposed area,
Fig. 5 Plot of s(r) for 2-DNA complex, shown at 0.5 au isosurface. Strongly
stabilizing interactions are shown in blue, and weakly stabilizing ones in green.
Table 5 Exposed surface area of drug in DNA dimer and octamer complexes
(Å2)
Dimer Octamer
1 67.3 63.2
2 157.0 117.1
3 208.1 189.7
4 RRS 158.5 124.8
4 SSS 155.8 131.2
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whereas 3 and SSS 4 lie between these extremes. These trends
are in accord with AIM data that show few drug–DNA contacts
for 1 but a large number of C–H…X contacts for 2.
Conclusions
We report hybrid QM/MM optimizations of the complexes of
several platinum drugs with a DNA octamer, with the goal of
examining and the effects of am(m)ine carrier on geometrical
and energetic aspects of binding. In particular, known or
promising drugs with larger chelating amine ligands are
compared with the archetypal drug cisplatin. This allows, for
instance, comparison of oxaliplatin (containing 1,2-DACH
ligand), or of the diastereomeric forms of lobaplatin. All
complexes considered distort DNA in broadly similar fashion,
but some subtle differences are evident, for which the drugs
considered fall into two broad categories, namely cisplatin and
the rest. This is most evident in the rise and roll parameters,
whereas other geometrical properties are either more uni-
formly shifted from free DNA values, or else no clear trend is
apparent. The extent to which the drug is exposed to its
environment when in complex with DNA has also been
examined: unsurprisingly, this is smallest for cisplatin and
largest for heptaplatin. Comparison of isomers shows that the
RRS form of lobaplatin is less exposed than the SSS form.
Binding energies of each drug to DNA have been calculated
in gas-phase and simulated aqueous solvation, and show clear
trends across amine ligands. Slightly surprisingly, cisplatin is
the most weakly bound drug to octameric DNA in both gas-
and aqueous-phase. Oxaliplatin shows slightly stronger bind-
ing, while heptaplatin is the most strongly bound of all drugs
considered. The SSS configuration of lobaplatin is almost as
strongly bound as heptaplatin, while its RRS diastereoisomer
is more weakly bound and comparable to oxaliplatin.
To examine these trends in more detail, the electron
density and related properties of a truncated model complex
with single-strand TGGT was examined. This showed little or
no difference in the covalent Pt–N7 binding to guanine, but
major differences in the non-covalent interactions between
drug and DNA. All complexes exhibit N–H…O6G39 hydrogen
bonding that are estimated on the basis of the electron density
to have similar strength, except for oxaliplatin that has a much
weaker and longer H-bond. Numerous other hydrogen bonds
are present in all complexes, often involving coordinated N–H
and O4 of T39, the p-system of T59 and phosphates in the DNA
backbone. C–H…O, C–H…p and C–H…H–C contacts are also
observed. This analysis also highlights contacts between the
O6 of 59 guanine and platinum in all complexes, approximately
in the apical position over the square-plane of coordinated
nitrogen. The long-range nature of this contact, and the low
electron density at the corresponding critical point, suggest
that this is not a fifth coordination site, but rather an outer-
sphere effect that makes only a small contribution to overall
binding.
By means of examination of the reduced density gradient
and the signs of the curvature of the electron density, such
contacts can be classified as strongly stabilizing, stabilizing, or
weakly stabilizing; no evidence of unfavorable steric clashes is
found in any complex, indicating that all non-covalent
interactions identified contribute to the overall stability of
binding of the drug to its target. Further support for this view
comes from approximate linear correlations between the sum
of the electron density at all bond critical points located and
the calculated binding energy. Thus, the importance of non-
covalent interactions in determining the covalent binding of
platinum drugs to DNA cannot be discounted.
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